July 11, 2024 – Talk Bio

Ipsen Licenses Novel Antibody-Drug Conjugate from Foreseen Biotechnology for Cancer Treatment

10 months ago talkbio0Tagged Antibody-Drug Conjugates, FS001, Global Licensing Agreement, Ipsen, Malignant Neoplasms

Ipsen, Foreseen Biotechnology, Antibody-Drug Conjugate (ADC), Cancer Treatment, Global Licensing Agreement, FS001

FTC to Sue Major PBMs Over Insulin and Drug Prices Amid Anticompetitive Concerns

10 months ago talkbio0Tagged anticompetitive, Benefit, health companies, Insulin, legal action, manager, PBMs, Pharmaceutical Services, Practice Experience, Prices, United States Federal Trade Commission

FTC, PBMs, Insulin Prices, Drug Prices, Anticompetitive Practices, Pharmacy Benefit Managers, Health Companies, Legal Action

Flagship’s Noubar Afeyan on Uncertainty, AI, and the Future of Biotechnology

10 months ago talkbio0Tagged Artificial Intelligence, Artificial Intelligence, biotech, Capital, Flagship, Future, innovation, Moderna, Noubar Afeyan, Pioneering, venture

, Noubar Afeyan, Flagship Pioneering, Biotechnology, Artificial Intelligence (AI), Uncertainty, Innovation, Future of Biotech, Moderna, Venture Capital,

Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment

10 months ago talkbio0Tagged Biological Response Modifier Therapy, Dermatitis, Atopic, Ebglyss, England, lebrikizumab, Moderate (severity modifier), Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Recommendation, Severe (severity modifier)

Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis

Flagship Raises $3.6 Billion to Support AI and Biotech Fusion

10 months ago10 months ago talkbio0Tagged AI, Biotechnology, startup

###